Grant: Vanier Canada Graduate Scholarships - Doctoral
University of Toronto
$50,000.00
Controlled release of chondroitinase ABC from composite injectable hyaluronan-methylcellulose hydrogels for spinal cord regeneration
FY 2012-13
Summary
In 2003-2004, over 950 traumatic spinal cord injuries (SCI) occurred in Canada. The most devastating aspect of this type of injury is the lack of functional recovery: a paraplegic will never regain the use of his/her legs. This is partly due to the secondary injury cascade that occurs following the initial mechanical trauma. The secondary injury includes the formation of a glial scar - a combination of cells and chondroitin sulphate proteoglycans (CSPGs). The glial scar is the body's way of sealing in the wound and preventing the spread of cellular damage; however it also blocks nerve regeneration. Recently, application of the bacterial enzyme chondroitinase ABC (ChABC) has been shown to promote regeneration of the injured spinal cord by degrading CSPGs in the glial scar. However, existing strategies for drug delivery to the spinal cord such as bolus injection or catheter do not provide the localized, sustained release, or minimal invasiveness that are required for clinical applications.
The goal of this project is to engineer a drug delivery system for the application of ChABC to the injured spinal cord that meets all of these criteria. Our lab has developed an injectable drug delivery system composed of polymer nanospheres containing the drug of choice embedded in a hyaluronan-methylcellulose hydrogel. By varying the nanosphere material as well as its properties, this system will be tailored to achieve linear release of ChABC for a period of at least 2 months. Once shown in vitro, the delivery system will be tested in an SCI animal model in terms of tissue diffusion, regeneration capacity, and functional benefit.
Almost 50% of traumatic SCIs are sustained by people under the age of 50, creating a major socio-economic burden in Canada. There is a clear need to develop therapies that can promote recovery after SCI. Results from this research could lead to such a therapy and will advance science towards innovations in the global knowledge-based economy.
Program
Vanier Canada Graduate Scholarships - Doctoral
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
405689-2011
Name nom
Pakulska, Malgosia
Department département
Chemical Engineering and Applied Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
50000
Program id
VCGS
Program name en
Vanier Canada Graduate Scholarships - Doctoral
Program name fr
Bourses d'études supérieures du Canada Vanier - Doctorat
Group en
Training programs
Group fr
Programmes de bourse
Committee code
1082
Committee name en
Vanier Selection Committee
Committee name fr
Comité de sélection Vanier
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
0
Application title
Controlled release of chondroitinase ABC from composite injectable hyaluronan-methylcellulose hydrogels for spinal cord regeneration
Keyword
NSERC
Application summary
In 2003-2004, over 950 traumatic spinal cord injuries (SCI) occurred in Canada. The most devastating aspect of this type of injury is the lack of functional recovery: a paraplegic will never regain the use of his/her legs. This is partly due to the secondary injury cascade that occurs following the initial mechanical trauma. The secondary injury includes the formation of a glial scar - a combination of cells and chondroitin sulphate proteoglycans (CSPGs). The glial scar is the body's way of sealing in the wound and preventing the spread of cellular damage; however it also blocks nerve regeneration. Recently, application of the bacterial enzyme chondroitinase ABC (ChABC) has been shown to promote regeneration of the injured spinal cord by degrading CSPGs in the glial scar. However, existing strategies for drug delivery to the spinal cord such as bolus injection or catheter do not provide the localized, sustained release, or minimal invasiveness that are required for clinical applications.
The goal of this project is to engineer a drug delivery system for the application of ChABC to the injured spinal cord that meets all of these criteria. Our lab has developed an injectable drug delivery system composed of polymer nanospheres containing the drug of choice embedded in a hyaluronan-methylcellulose hydrogel. By varying the nanosphere material as well as its properties, this system will be tailored to achieve linear release of ChABC for a period of at least 2 months. Once shown in vitro, the delivery system will be tested in an SCI animal model in terms of tissue diffusion, regeneration capacity, and functional benefit.
Almost 50% of traumatic SCIs are sustained by people under the age of 50, creating a major socio-economic burden in Canada. There is a clear need to develop therapies that can promote recovery after SCI. Results from this research could lead to such a therapy and will advance science towards innovations in the global knowledge-based economy.